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Abstract
Background: Cystic Fibrosis (CF) is a life-shortening genetic disease in which ~80% of deaths result from loss of
lung function linked to inflammation due to chronic bacterial infection (principally Pseudomonas aeruginosa).
Pulmonary exacerbations (intermittent episodes during which symptoms of lung infection increase and lung
function decreases) can cause substantial resource utilization, morbidity, and irreversible loss of lung function.
Intravenous antibiotic treatment to reduce exacerbation symptoms is standard management practice. However, no
prospective studies have identified an optimal antibiotic treatment duration and this lack of objective data has
been identified as an area of concern and interest.
Methods: We have retrospectively analyzed pulmonary function response data (as forced expiratory volume in one
second; FEV1) from a previous blinded controlled CF exacerbation management study of intravenous ceftazidime/
tobramycin and meropenem/tobramycin in which spirometry was conducted daily to assess the time course of
pulmonary function response.
Results: Ninety-five patients in the study received antibiotics for at least 4 days and were included in our analyses.
Patients received antibiotics for an average of 12.6 days (median = 13, SD = 3.2 days), with a range of 4 to 27 days.
No significant differences were observed in mean or median treatment durations as functions of either treatment
group or baseline lung disease stage. Average time from initiation of antibiotic treatment to highest observed FEV1
was 8.7 days (median = 10, SD = 4.0 days), with a range of zero to 19 days. Patients were treated an average of 3.9
days beyond the day of peak FEV1 (median = 3, SD = 3.8 days), with 89 patients (93.7%) experiencing their peak
FEV1 improvement within 13 days. There were no differences in mean or median times to peak FEV1 as a function
of treatment group, although the magnitude of FEV1 improvement differed between groups.
Conclusions: Our results suggest that antibiotic response to exacerbation as assessed by pulmonary function is
essentially complete within 2 weeks of treatment initiation and relatively independent of the magnitude of
pulmonary function response observed.
Introduction
Cystic Fibrosis (CF) is a life-shortening genetic disease
in which ~80% of deaths result from loss of lung func-
tion linked to inflammation caused by chronic bacterial
lung infection (principally Pseudomonas aeruginosa)
[1,2]. Pulmonary exacerbations (intermittent episodes
during which symptoms of lung infection increase and
lung function decreases) can cause substantial resource
utilization [3], morbidity [4], and irreversible loss of
lung function [5].
A number of different signs, symptoms, and test
results can contribute to the diagnosis of CF pulmonary
exacerbation [2,4], with precipitous loss of forced
expiratory volume in 1 second (FEV1)m o s ts t r o n g l y
associated with exacerbation diagnosis in patients old
enough to reliably perform spirometry [6]. Because loss
of lung function is the underlying cause of a majority of
CF deaths [1], management of CF exacerbations
includes an understandable emphasis on recovery of
lung function [7]. Unfortunately, many patients fail to
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One study has shown that 43% of patients treated for
pulmonary exacerbation failed to completely reach their
pre-exacerbation pulmonary function, and 24% failed to
achieve even 95% of their pre-exacerbation function [5].
Administration of systemic antibiotics is an essential
component of CF exacerbation management, particularly
in patients chronically infected with Pseudomonas aeru-
ginosa [7,8]. Three blinded placebo-controlled clinical
studies failed to demonstrate a significant antipseudo-
monal antibiotic effect on increased respiratory signs
and symptoms associated with exacerbation [9-11] and
only one of these studies could attribute a significant
improvement in FEV1 % predicted to antibiotic treat-
ment [11]. Regardless, treatment guidelines suggest that
antibiotics be administered for a CF exacerbation “for a
minimum of 10 days but often will be extended depend-
ing on the time course until clinical improvement is
seen and the improvement or lack thereof, of pulmonary
function tests” [7]. This guidance, which is based more
on experience and consensus than evidence, does not
address the question of when antibiotic regimens should
be adjusted or abandoned entirely in the absence of
complete recovery after extended treatment. A recent
Cochrane review noted this problem and suggested that
a randomized controlled trial comparing different anti-
biotic treatment durations could have important clinical
and financial implications [12]. Similarly, a recent CF
Foundation consensus document concluded that “there
is insufficient evidence to recommend an optimal dura-
tion of antibiotic treatment of an acute exacerbation,”
noting that duration of therapy is “an important ques-
tion that should be studied further” [8].
We have retrospectively analyzed data from a previous
study of antibiotic treatment of CF exacerbation in
which spirometry was conducted daily [13]. In this mul-
ticenter study, treatment duration was left to the indivi-
dual investigator’s discretion based upon their current
standards of exacerbation management. Our purpose
was to characterize FEV1 response to antibiotic therapy
as a function of time to determine if FEV1 response
continued or was attenuated with extended treatment.
Methods
Data were obtained from a previous blinded, rando-
mized study comparing treatment with intravenous cef-
tazidime plus tobramycin (ceftaz/tobra) to treatment
with meropenem plus tobramycin (mero/tobra) for
acute pulmonary exacerbation [13]. This previous study
was conducted in accordance with the recommendations
found in the Helsinki Declaration of 1975. The study
protocol and informed consent were approved by the
Institutional Review Board for Human Studies at each
site. Informed consent was obtained from each subject.
To be included in the current analyses, patients had to
have been enrolled in the blinded, randomized portion
of the previous study, have had spirometry performed at
treatment initiation (Day 0) and have received four or
more consecutive days of treatment with ceftaz/tobra or
mero/tobra from initiation. Baseline lung disease stage
("early,” FEV1 ≥ 70% predicted; “intermediate,” FEV1
between 40% and 69% predicted; “advanced,” FEV1 <
40% predicted), antibiotic treatment assignments, and all
available daily spirometric measures beginning at Day 0
were collected for each patient. Relative change in FEV1
was calculated by subtracting a patient’sD a y0F E V 1
value from the FEV1 value on any subsequent treatment
day, and then dividing by the Day 0 value. Relative
change values were expressed as percentages. Peak
change in FEV1 was defined as the largest relative
increase in FEV1 observed after initiation of treatment
for each subject. Differences in median treatment dura-
tions and elapsed times from treatment initiation to
observation of peak FEV1 were studied as functions of
antibiotic treatment received and baseline lung disease
stage by Wilcoxon rank sum tests. Differences in abso-
lute and relative change in FEV1 from baseline between
groups were analyzed by t tests.
Results
Ninety-five patients (50 treated with ceftaz/tobra and
45 treated with mero/tobra) met inclusion criteria and
were included in this retrospective analysis. At initia-
tion of treatment, 11 patients (11.6%) had an FEV1 of
≥70% predicted, 46 (48.4%) had an FEV1 of between
40% and 70% predicted, and 38 (40.0%) had an FEV1
of < 40% predicted. Baseline FEV1 values (in liters) for
subgroups are provided in Table 1. Patients were trea-
ted with antibiotics for an average of 12.6 days (med-
ian = 13, SD = 3.2 days), with a range of 4 to 27 days
(Table 1). Seventy-six patients (80%) had completed
antibiotic treatment by 14 days, and 96.8% had com-
pleted treatment by 16 days (Figure 1). No significant
differences were observed in mean or median antibio-
tic treatment durations as functions of either antibiotic
treatment received or baseline lung disease stage,
although there was a trend towards longer median
treatment durations with mean greater impairment of
baseline FEV1 (Table 1).
The average time from initiation of antibiotic treat-
ment to the highest observed FEV1 for all patients was
8.7 days (median = 10, SD = 4.0 days), with a range of
zero to 19 days (Table 1). Two patients (2.1%) did not
experience an increase in FEV1 over their baseline
values, despite being treated with antibiotics for 8 and
15 days. Twelve patients (12.6%) experienced their
greatest relative improvement in FEV1 on their final day
of antibiotic treatment, which occurred on average 11.5
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Patients were treated with antibiotics for an average of
3.9 days beyond the day that their peak FEV1 was
observed (median = 3, SD = 3.8 days). The patient trea-
ted for the longest duration (27 days) was also the
patient treated for the longest period after recording his
or her peak FEV1 (at day 5). In all, 70 patients (73.7%)
had already experienced their peak improvement in
FEV1 by 11 days of antibiotic treatment, and 89 patients
(93.7%) had experienced their peak improvement in
FEV1 by 13 days of treatment. There was no significant
difference observed in median time to peak FEV1
response observed between patients treated with ceftaz/
tobra and those treated with mero/tobra (10 versus 9
days, P = 0.52)(Figures 2 and 3A). In contrast, mean
time to peak FEV1 response was impacted by baseline
lung disease stage, with patients entering the study with
an FEV1 < 40% predicted requiring a significantly longer
median treatment duration to achieve their peak FEV1
response compared with those patients with a baseline
FEV1 between 40% and 69% predicted (8.0 versus 9.9
days, P = 0.041) (Figures 2 and 3B).
For the entire population, patients experienced an
average peak increase in FEV1 of 0.55 liters, from a
baseline average of 1.40 liters to a peak average of 1.95
liters (Table 2). In relative terms, patients experienced
an average 47.2% increase over their baseline FEV1 at
peak. Patients receiving mero/tobra experienced a
greater average increase in FEV1 from baseline to their
peak measure than patients receiving ceftaz/tobra (0.65
liters versus 0.46 liters; p = 0.033). However, when indi-
vidual peak FEV1 increases were normalized for baseline
Table 1 Treatment Duration and Time to Peak FEV1 Measure
Mean,days ± SD Median,days Range, days (min - max) Interquartile Range, days
Antibiotic Treatment Duration
All patients (n = 95) 12.6 ± 3.2 13 23 (4 - 27) 3
ceftaz/tobra treated (n = 50) 12.5 ± 2.8 12.5 12 (4 - 16) 3.75
mero/tobra treated (n = 45) 12.8 ± 3.6 13 21 (6 - 27) 3
FEV1 ≥ 70% predicted (n = 11) 11.9 ± 2.4 12 8 (7 - 15) 3
FEV1 40% - 69% predicted (n = 46) 12.3 ± 2.8 13 15 (6 - 21) 3
FEV1 < 40% predicted (n = 38) 13.2 ± 3.8 14 23 (4 - 27) 3
Time to Peak FEV1 Measure
All patients 8.7 ± 4.0 10 19 (0 - 19) 6.5
ceftaz/tobra treated 8.9 ± 4.0 10 15 (1 - 16) 6.75
mero/tobra treated 8.5 ± 4.3 9 19 (0 - 19) 5
FEV1 ≥ 70% predicted 7.9 ± 3.3 7 12 (4 - 15) 5
FEV1 40% - 69% predicted 8.0 ± 4.2 9.5 15 (0 - 15) 6
FEV1 < 40% predicted 9.9 ± 3.6 10 16 (3 - 19) 4.75
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Figure 1 Distribution of antibiotic treatment durations. The gray bars show the distribution of antibiotic treatment duration in days for the
95 study patients (left vertical axis). The black line represents the cumulative percentage of patients having completed treatment by a given
duration (right vertical axis).
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mero/tobra patients was not significantly different (p =
0.056) than the 39.3% relative increase experienced by
ceftaz/tobra patients. Average peak increases in FEV1
were not significantly different for patients with different
baseline lung disease stages, ranging from 0.51 liters to
0.70 liters (Table 2).
Discussion
There may be no more challenging aspect of CF exacer-
bation management than determining an “appropriate”
or “optimal” use of systemic antibiotics [8]. In addition
to the question of which organisms within complex
multispecies lung infections should be targeted (and by
extension, which specific antibiotics should be chosen),
the question of how long antibiotics should be adminis-
tered has yet to be meaningfully explored [8,12]. In the
past, CF treatment guidelines have suggested that treat-
ment duration should be determined empirically by “the
improvement, or lack thereof” of pulmonary function
[7]. This suggestion is logical, in that loss of FEV1 is a
strong predictor of exacerbation diagnosis [6], and anti-
biotic therapy has been shown to significantly improve
lung function in CF patients experiencing an exacerba-
tion [11]. Unfortunately, many patients treated for a CF
exacerbation do not fully recover lung function lost
immediately prior to intervention [5], creating a
dilemma for the treating clinician: if a patient has not
fully recovered lost lung function following weeks of
antibiotic treatment, should treatment be extended? At
what point does the clinician accept that the patient will
not fully recover lung function on the current regimen,
and that continued antibiotic treatment may be futile
and possibly deleterious?
The reasons that some patients fail to completely
recover lost lung function following exacerbation [5]
remain unknown. It may be that antibiotic choices and/
or treatment durations made for some patients have
been suboptimal, or simply that irreversible lung
damage has occurred in some patients, or both. It can
be argued, however, that an “optimal” duration for any
antibiotic therapy would be one that includes an
observed peak increase in FEV1, regardless of the magni-
tude of the increase observed. In practice, it is impossi-
ble to recognize that moment in time when a patient is
experiencing his or her peak FEV1 improvement, as this
is an inherently retrospective analysis. It is possible,
however, to retrospectively review a series of treatment
courses and ask whether the timing of peak responses
adhere to a consistent pattern that could be useful in
predicting future response time courses. Recently, a ret-
rospective analysis of 1,535 patients treated for exacer-
bation while participating in the US CF Twin and
Sibling Study between 2000-2007 showed that, on aver-
age, lung function recovery reached a plateau after 8
and 10 days of treatment [14] a result similar to that
observed in a small prospective study by Regelmann
et al. [11] two decades earlier. Our results compliment
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Time (days)
ceftazidime/tobramycin treated
(N = 50)
meropenem/tobramycin treated
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(N = 11)
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baseline FEV1  < 40% predicted
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Figure 2 Treatment duration and time to peak response by subgroups. Box and whisker plots of antibiotic treatment duration (white
boxes) and time to peak observed FEV1 measure (gray boxes) among patients stratified by antibiotic treatment (ceftaz/tobra and mero/tobra)
and by lung disease stage (FEV1 ≥ 70% predicted, 40- 69% predicted, and <40% predicted).
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been able to analyze daily PFT measures for individual
patients to confirm that attainment of peak FEV1 occurs
fairly consistently within 2 weeks of initiation of antibio-
tic treatment.
There are several limitations to the current analysis,
not the least of which is that patients were not consis-
tently treated for an extended duration (e.g., 3 or more
weeks) in order to derive more accurate time to peak
FEV1 response curves. It is possible that if all patients
(and particularly those treated for the shortest dura-
tions) had been treated longer, they may have experi-
enced higher peak FEV1 values later in treatment. For
instance, the mean peak improvement in FEV1 for the
10 patients treated between 4 and 8 days was only 0.46
liters (median = 0.26, SD = 0.64 liters) (Table 3), lower
than the population average of 0.55 liters (Table 2).
However, only 2 of these patients experienced their
peak FEV1 on their final day of treatment, and although
the median treatment duration within this subgroup was
7 days, the median time to peak FEV1 response among
these patients was only 4.5 days. Comparison of out-
comes for the 43 patients treated between 9 and 13 days
with the 42 patients treated for 14 days or longer sug-
gests that little advantage was obtained by extended
treatment, with 85.7% of patients treated for greater
than 14 days experiencing their peak FEV1 before 14
days treatment (Table 3). Average peak FEV1
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than 14 days compared to those treated for 9 to 13 days
(0.50 versus 0.62 liters; P = 0.17). Average peak FEV1
improvement for the 8 patients treated for at least 16
days was 0.40 liters (median = 0.36, SD = 0.20 liters),
with half experiencing their peak FEV1 by day 12.
Although investigators may have extended the treatment
of these patients on the basis of a poor initial FEV1
response, extending treatment did not result with these
patients having a higher overall FEV1 response than
others in the study.
A caveat of this retrospective study is that patients
had to have had at least one ceftazidime and merope-
nem susceptible strain of P. aeruginosa isolated from
their respiratory secretions at baseline in order to be eli-
gible for randomization [13]. Although it has been sug-
gested previously that response to antipseudomonal
antibiotics (and particularly to ceftazidime plus tobramy-
cin) is independent of in vitro susceptibility test results
in CF [15], it may be that time to peak FEV1 response
may be impacted by the absence of antibiotic susceptible
strains in patients experiencing an exacerbation.
It is not our intention to discourage treating physi-
cians from diligently pursuing other treatable causes of
failure to improve FEV1 to pre-exacerbation average or
recent best FEV1 in patients who have experienced pul-
monary exacerbation. However, these data suggest that
continued application of a given antibiotic intervention
beyond approximately two weeks is unlikely to result in
additional patient benefit with respect to FEV1.R e s u l t s
from this retrospective analysis suggest hypotheses that
might be tested in prospective CF exacerbation clinical
trials. First, median times to peak FEV1 response for the
two antibiotic treatments were not significantly different
(Figures 2 and 3A) despite a suggestion of a difference
in the magnitude of peak FEV1 response to each treat-
ment (Table 2 and Figure 4). This result implies that
antibiotic treatment duration and FEV1 response
Table 2 FEV1 Measures
Subject Group Mean,liters ± SD Median,liters Range, liters (min - max)
Baseline FEV1
All patients (n = 95) 1.40 ± 0.71 1.19 3.09 (0.44 - 3.53)
ceftaz/tobra treated (n = 50) 1.37 ± 0.71 1.13 3.09 (0.44 - 3.53)
mero/tobra treated (n = 45) 1.44 ± 0.71 1.37 2.99 (0.48 - 3.47)
FEV1 ≥ 70% predicted (n = 11) 2.46 ± 0.87 2.72 2.38 (1.15 - 3.53)
FEV1 40% - 69% predicted (n = 46) 1.54 ± 0.56 1.47 2.52 (0.56 - 3.08)
FEV1 < 40% predicted (n = 38) 0.93 ± 0.30 0.90 1.43 (0.44 - 1.87)
Observed Peak FEV1
All patients 1.95 ± 0.87 1.72 3.62 (0.67 - 4.29)
ceftaz/tobra treated 1.83 ± 0.85 1.55 3.29 (0.67 - 3.96)
mero/tobra treated 2.09 ± 0.88 1.78 2.99 (0.48 - 4.29)
FEV1 ≥ 70% predicted 3.17 ± 1.01 3.71 2.99 (1.30 - 4.29)
FEV1 40% - 69% predicted 2.05 ± 0.71 2.05 2.76 (0.84 - 3.60)
FEV1 < 40% predicted 1.48 ± 0.59 1.39 2.44 (0.67 - 3.11)
FEV1 Change, Baseline to Peak
All patients 0.55 ± 0.43 0.46 2.19 (0.0 - 2.19)
ceftaz/tobra treated 0.46 ± 0.36 0.39 1.50 (0.05 - 1.55)
mero/tobra treated 0.65 ± 0.49 0.55 2.19 (0.0 - 2.19)
FEV1 ≥ 70% predicted 0.70 ± 0.46 0.43 1.40 (0.15 - 1.55)
FEV1 40% - 69% predicted 0.51 ± 0.41 0.46 2.19 (0.0 - 2.19)
FEV1 < 40% predicted 0.56 ± 0.45 0.43 1.93 (0.01 - 1.94)
Table 3 Relationships between Treatment Duration and Observed Peak FEV1
Treatment Duration Window
4-8 Days 9-13 Days 14+ Days
Patients, n 10 43 42
Median Treatment Duration, days 7 12 14
Median Peak FEV1 Observation, days 4.5 8 11.5
Mean Peak FEV1 Increase, liters ± SD 0.46 ± 0.64 0.62 ± 0.43 0.50 ± 0.38
Patients Reaching Peak FEV1 before Duration Window, n (%) 3 (30.0%) 22 (51.2%) 36 (85.7%)
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magnitude of an antibiotic response is unlikely to be
improved by extending treatment beyond 14 days. The
profiles of mean daily changes in FEV1 from baseline
through day 14 by treatment group are consistent with
this hypothesis, in that the relative amplitudes of the
profiles differ but their shapes are similar (Figure 4). A
blinded study in which subjects are randomized to
receive either 14 days of treatment or the current prac-
tice of extended treatment at clinician discretion [7]
could address the question of whether additional bene-
fit (or harm) is associated with extended treatment.
Second, 89 of 95 patients (93.7%) experienced their
highest FEV1 on or before day 13 of treatment, and
only 12 (12.6%) patients experienced their peak FEV1
on their last day of treatment, including 7 who were
treated less than 12 days. These results suggest that
limiting treatment protocols to 14 days duration for
the purposes of comparing responses to different anti-
biotic treatments would be both ethical and likely to
detect true differences between treatments. Third,
there was a noticeable trend with respect to the impact
of baseline lung function on time to peak FEV1
response, with patients having a baseline FEV1 ≥ 70%
predicted having a significantly shorter median time to
peak response (7 days) whenc o m p a r e dt op a t i e n t s
with baseline FEV1 < 40% predicted (10 days, P =
0.041) (Table 1; Figures 2 and 3B). Interestingly, the
magnitude of improvement in FEV1 (in liters) was
fairly consistent across lung disease stages (Table 2).
These results suggest that baseline lung disease stage
should be accounted for in the design and analysis of
prospective exacerbation studies. Finally, our analyses
have necessarily been limited to the question of when
peak FEV1 was observed during antibiotic treatment,
but the implication that FEV1 increase following
exacerbation is limited to that period when antibiotics
are administered may not be justified. Unfortunately,
subject spirometry after cessation of antibiotics was
not available for this retrospective analysis, but a pro-
spective trial of antibiotic treatment duration should
consider the possibility that additional recovery of
FEV1 may occur after antibiotic treatment is halted.
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